Recent clinical developments highlight novel antibody-based therapeutics showing promise across cancer and autoimmune disorders. Aptevo Therapeutics’ mipletamig updated data reveal an 85% remission rate in acute myeloid leukemia, while Immuneering’s MEK inhibitor demonstrates potential against pancreatic cancer. Additionally, Kyverna Therapeutics' CD19-targeted CAR T-cell therapy shows pioneering success in treating severe autoimmune polyneuritis, marking a milestone in immunotherapy applications beyond oncology.